Get the Stockscreener App
2.06
4.63%
-0.10
Okyo Pharma Limited stock is traded at $2.06, with a volume of 177.27K.
It is down -4.63% in the last 24 hours and down -20.77% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$2.16
Open:
$2.14
24h Volume:
177.27K
Relative Volume:
1.17
Market Cap:
$77.48M
Revenue:
-
Net Income/Loss:
$-13.27M
P/E Ratio:
-12.56
EPS:
-0.164
Net Cash Flow:
$-7.70M
1W Performance:
+7.85%
1M Performance:
-20.77%
6M Performance:
-18.58%
1Y Performance:
+94.34%
1-Day Range:
$1.92
$2.14
1-Week Range:
$1.90
$2.40
52-Week Range:
$0.9016
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
2.06 | 81.24M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-25 | Initiated | B. Riley Securities | Buy |
Okyo Pharma Limited Stock (OKYO) Latest News
Small cap wrap: AtaiBeckley, OKYO Pharma, New Era Energy & Digital, Century Lithium… - Proactive financial news
OKYO Pharma reports favorable outcomes from Phase 2 neuropathic corneal pain study - Proactive Investors
OKYO’s urcosimod shows potential nerve regeneration in corneal pain trial By Investing.com - Investing.com Australia
OKYO Pharma Reports Positive Phase 2 Results for Urcosimod in Neuropathic Corneal Pain - TipRanks
OKYO Pharma Reports Encouraging Phase 2 Trial Results for Urcosimod in Neuropathic Corneal Pain - Quiver Quantitative
OKYO Pharma Announces New Data Showing Favorable Corneal - GlobeNewswire
B. Riley Begins Coverage on OKYO Pharma (NASDAQ:OKYO) - Defense World
B. Riley Initiates Coverage on OKYO Pharma (NASDAQ:OKYO) - MarketBeat
B. Riley Initiates Coverage on OKYO Pharma With Buy Rating, $5 Price Target - marketscreener.com
B.Riley initiates coverage on OKYO Pharma stock with Buy rating - Investing.com Nigeria
How OKYO Pharma Limited (OK11) stock compares with top peersGlobal Markets & Long-Term Safe Investment Plans - Newser
What is the fair value estimate for OKYO Pharma Limited (OK11) stock in 2025Market Sentiment Report & Technical Pattern Alert System - Newser
Is OKYO Pharma Limited (OK11) stock a top pick for value investors2025 Trade Ideas & AI Powered Market Entry Strategies - Newser
Okyo Pharma chairman acquires 27,051 company shares - MSN
Is OKYO Pharma Limited stock trading near support levelsWeekly Profit Analysis & Daily Chart Pattern Signal Reports - Newser
OKYO Pharma chairman-linked entity acquires additional shares on NASDAQ By Investing.com - Investing.com Australia
OKYO Pharma chairman-linked entity acquires additional shares on NASDAQ - Investing.com
OKYO Pharma’s Chairman Increases Stake Amidst Phase 2 Trial Completion - TipRanks
Gabriele Cerrone increases stake in OKYO Pharma with share purchase - Investing.com
OKYO Pharma Limited Executive Chairman Gabriele Cerrone Acquires Additional Shares in Company - Quiver Quantitative
Gabriele Cerrone increases stake in OKYO Pharma with share purchase By Investing.com - Investing.com UK
OKYO Pharma (NASDAQ: OKYO) chairman raises holding after buying 27,051 shares - Stock Titan
OKYO Pharma Announces Chairman and Founder Acquires Shares - GlobeNewswire
Why OKYO Pharma Limited stock is a must watch in 2025Market Growth Report & Comprehensive Market Scan Reports - Newser
OKYO Pharma executive chair increases stake with additional share purchase - Proactive financial news
OKYO Pharma (OKYO) Stock Analysis Report | Financials & Insights - Benzinga
Holdings of OKYO Pharma Limited (OKYO) are aligned with the stars - Setenews
Decliners Report: Will OKYO Pharma Limited stock remain a Wall Street favoriteRecession Risk & Advanced Swing Trade Entry Plans - moha.gov.vn
Okyo Pharma chairman acquires 82,018 company shares - MSN
Panetta Partners increases stake in OKYO Pharma with purchase of 82,018 shares - Investing.com Australia
OKYO Pharma founder increases his buys shares - Proactive financial news
Operating cash flow per share of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Okyo Pharma chairman increases stake with new share acquisition By Investing.com - Investing.com Nigeria
OKYO Pharma stock rises after Chairman increases stake By Investing.com - Investing.com Nigeria
OKYO Pharma stock rises after Chairman increases stake - Investing.com India
OKYO Pharm Chairman and Founder acquires shares - MSN
OKYO Pharma’s Chairman Increases Stake with Recent Share Acquisition - TipRanks
Okyo Pharma chairman increases stake with new share acquisition - Investing.com India
OKYO Pharma Limited Executive Chairman Acquires Additional Shares, Totaling 10.5 Million Holdings - Quiver Quantitative
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):